Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions
Interventions
ABT-263
Locations
10
United States
Moores Cancer Center at UC San Diego /ID# 5566
La Jolla, California, United States
Dana-Farber Cancer Institute /ID# 5547
Boston, Massachusetts, United States
University of Nebraska Medical Center /ID# 12261
Omaha, Nebraska, United States
North Shore University Hospital /ID# 12267
New Hyde Park, New York, United States
University of Texas MD Anderson Cancer Center /ID# 5575
Houston, Texas, United States
Northwest Medical Specialties - Tacoma /ID# 26428
Tacoma, Washington, United States
Start Date
July 25, 2007
Primary Completion Date
May 12, 2022
Completion Date
May 12, 2022
Last Updated
June 13, 2023
NCT06846671
NCT07218341
NCT07030400
NCT05006716
NCT07277231
NCT06859424
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions